Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

25.36 -0.07 (-0.29%)

Delayed Quote Updated: 11:52 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Cassava Sciences Stock Continues Showing Rising Relative Strength ↗

January 16, 2024

Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.

Via Investor's Business Daily

Why NASDAQ:AMPH is Poised for High Growth. ↗

January 16, 2024

Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics.

Via Chartmill

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. ↗

January 02, 2024

Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing?

Via Chartmill

Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

Via ACCESSWIRE

Should you consider NASDAQ:AMPH for growth investing? ↗

December 26, 2023

Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing?

Via Chartmill

Why NASDAQ:AMPH qualifies as a high growth stock. ↗

December 12, 2023

Why the growth investor may take a look at AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH).

Via Chartmill

Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study ↗

December 28, 2023

On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before.

Via Investor's Business Daily

Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher ↗

December 26, 2023

On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before.

Via Investor's Business Daily

3 Reasons Why Amphastar Is a Great Growth Stock ↗

December 26, 2023

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great...

Via Talk Markets

3 Stocks at the Forefront of Medical Innovation ↗

December 25, 2023

Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.

Via InvestorPlace

Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗

December 21, 2023

On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.

Via Investor's Business Daily

TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗

December 07, 2023

TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93.

Via Investor's Business Daily

Exploring NASDAQ:AMPH's CANSLIM characteristics. ↗

December 05, 2023

Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing?

Via Chartmill

Exploring growth characteristics of AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH). ↗

November 21, 2023

Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.

Via Chartmill

Evaluating NASDAQ:AMPH for Growth Investment Opportunities. ↗

November 14, 2023

High growth, ROE and relative strength for AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), growth investors may appreciate this.

Via Chartmill

These Three Biotech Stocks Are Trading At A Discount ↗

November 23, 2023

Investors exposed to the biotech sector have seen mixed results this year.

Via Talk Markets

Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

Via ACCESSWIRE

Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade ↗

November 10, 2023

Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before.

Via Investor's Business Daily

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

November 09, 2023

Via ACCESSWIRE

7 Healthcare Stocks That Are Poised to Become the Next Unicorns ↗

November 09, 2023

Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments.

Via InvestorPlace

Recap: Amphastar Pharma Q3 Earnings ↗

November 08, 2023

Via Benzinga

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023

November 08, 2023

Via ACCESSWIRE

Earnings Preview For Amphastar Pharma ↗

November 07, 2023

Via Benzinga

Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday ↗

November 09, 2023

U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade ↗

November 08, 2023

On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.

Via Investor's Business Daily

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023

November 01, 2023

Via ACCESSWIRE

Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗

October 31, 2023

Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 ↗

October 16, 2023

Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating ↗

September 27, 2023

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Via Investor's Business Daily

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.